More recently, STING activation has become the hallmark of AML by triggering p53-independent apoptosis, and STING agonists have shown a synergistic effect with BH3-mimetics in TP53-mutant blood cancers [173]. The gene discussed is TP53; the disease is hematopoietic and lymphoid system neoplasm.